Regulatory Filings and Submissions

>

Latest News

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
Celltrion’s YUFLYMA (adalimumab-aaty) Receives FDA Interchangeable Designation as Biosimilar to Humira (adalimumab)

April 17th 2025

Celltrion’s adalimumab-aaty is designated interchangeable as a high-concentration (100mg/mL) and citrate-free formulation of adalimumab.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
FDA Approves Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

April 15th 2025

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
EC Approves Imfinzi for Treatment of LS-SCLC

March 26th 2025

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
Australia Regulatory Authority Declines Approval of Eisai’s Lecanemab for Early Alzheimer’s Disease

March 11th 2025

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC

March 10th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.